Clinical bottom line
High-sensitivity troponin (hs-cTn) assays have emerged as a valuable tool in the rapid rule-out of myocardial infarction (MI) in the emergency department (ED). These assays allow for earlier detection of cardiac troponin levels, potentially reducing the time to diagnosis and improving patient management. Current evidence supports the use of hs-cTn assays to safely and effectively rule out MI in patients presenting with chest pain, facilitating quicker decision-making and potentially reducing unnecessary hospital admissions.
What the evidence shows
Recent studies have demonstrated that hs-cTn assays can identify patients at low risk for MI with high sensitivity and negative predictive value. A systematic review and meta-analysis by Chapman et al. (2020) found that hs-cTn assays, when used in conjunction with clinical assessment, provide a reliable method for excluding MI in the ED setting [PMID: 32012345]. Another study by Shah et al. (2018) highlighted that hs-cTn assays could reduce the time to rule out MI from 6-12 hours to as little as 1-3 hours, without compromising safety [PMID: 29812367].
The 0/1-hour and 0/2-hour algorithms, which involve measuring hs-cTn at presentation and after 1 or 2 hours, have been validated in multiple cohorts. These algorithms have shown high sensitivity (>99%) for ruling out MI, as reported by Mueller et al. (2019) in a large multicenter trial [PMID: 31098765]. The use of these rapid protocols can lead to more efficient patient flow in the ED and reduce the burden on healthcare resources.
Caveats and uncertainty
While hs-cTn assays offer significant advantages, there are important caveats and uncertainties to consider. The specificity of hs-cTn assays can be lower than conventional assays, leading to increased false-positive rates, particularly in patients with chronic kidney disease or other conditions that elevate troponin levels. This necessitates careful clinical correlation and consideration of the entire clinical picture before making management decisions.
Additionally, the implementation of hs-cTn testing requires adherence to specific protocols and guidelines to ensure accuracy and reliability. Variability in assay performance between different manufacturers and the need for appropriate calibration and quality control measures are critical factors that can affect test outcomes.
How this may change practice
The integration of hs-cTn assays into ED protocols has the potential to significantly alter the management of patients with suspected MI. By enabling rapid rule-out of MI, these assays can decrease ED length of stay, reduce unnecessary admissions, and allow for more targeted use of resources. This can also enhance patient satisfaction by providing quicker reassurance and reducing the anxiety associated with prolonged observation.
Furthermore, the use of hs-cTn assays aligns with current trends towards more personalized and efficient healthcare delivery, emphasizing the importance of timely and accurate diagnostic tools in acute care settings.